153 related articles for article (PubMed ID: 37012089)
1. Impact of soluble tumor necrosis factor-related apoptosis-inducing ligand released by engineered adipose mesenchymal stromal cells on white blood cells.
Casari G; Dall'Ora M; Melandri A; Masciale V; Chiavelli C; Prapa M; Neri G; Spano MC; Murgia A; D'Esposito A; Baschieri MC; Ceccherelli GB; Dominici M; Grisendi G
Cytotherapy; 2023 Jun; 25(6):605-614. PubMed ID: 37012089
[TBL] [Abstract][Full Text] [Related]
2. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
3. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
Yu R; Deedigan L; Albarenque SM; Mohr A; Zwacka RM
Cell Death Dis; 2013 Feb; 4(2):e503. PubMed ID: 23429289
[TBL] [Abstract][Full Text] [Related]
4. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
[TBL] [Abstract][Full Text] [Related]
5. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer.
Spano C; Grisendi G; Golinelli G; Rossignoli F; Prapa M; Bestagno M; Candini O; Petrachi T; Recchia A; Miselli F; Rovesti G; Orsi G; Maiorana A; Manni P; Veronesi E; Piccinno MS; Murgia A; Pinelli M; Horwitz EM; Cascinu S; Conte P; Dominici M
Sci Rep; 2019 Feb; 9(1):1788. PubMed ID: 30742129
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.
Yuan Z; Kolluri KK; Sage EK; Gowers KH; Janes SM
Cytotherapy; 2015 Jul; 17(7):885-96. PubMed ID: 25888191
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK
Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
Liu XS; Zhu Y; Han WN; Li YN; Chen LH; Jia W; Song CJ; Liu F; Yang K; Li Q; Jin BQ
Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
10. [Interleukin-12 enhanced tumor necrosis factor related apoptosis-inducing ligand TRAIL-induced apoptosis in human hepatocellular carcinoma by inhibiting expression of survivin].
He SQ; Chen Y; Chen XP; Zhang WG; Wang HP; Zhang BX
Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):453-7. PubMed ID: 12895357
[TBL] [Abstract][Full Text] [Related]
11. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.
Yan C; Li S; Li Z; Peng H; Yuan X; Jiang L; Zhang Y; Fan D; Hu X; Yang M; Xiong D
Mol Pharm; 2013 Jan; 10(1):142-51. PubMed ID: 23121392
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Biosafety Evaluation of Genetically Modified Human Adipose Tissue-Derived Mesenchymal Stem Cells for Clinical Applications to Brainstem Glioma.
Choi SA; Yun JW; Joo KM; Lee JY; Kwak PA; Lee YE; You JR; Kwon E; Kim WH; Wang KC; Phi JH; Kang BC; Kim SK
Stem Cells Dev; 2016 Jun; 25(12):897-908. PubMed ID: 27151205
[TBL] [Abstract][Full Text] [Related]
13. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.
Vigneswaran N; Baucum DC; Wu J; Lou Y; Bouquot J; Muller S; Zacharias W
BMC Cancer; 2007 Jun; 7():108. PubMed ID: 17592646
[TBL] [Abstract][Full Text] [Related]
14. Association between laryngeal squamous cell carcinoma and polymorphisms in tumor necrosis factor related apoptosis induce ligand (TRAIL), TRAIL receptor and sTRAIL levels.
Verim A; Turan S; Farooqi AA; Kahraman OT; Tepe-Karaca C; Yildiz Y; Naiboglu B; Ozkan NE; Ergen A; Isitmangil GA; Yaylim I
Asian Pac J Cancer Prev; 2014; 15(24):10697-703. PubMed ID: 25605161
[TBL] [Abstract][Full Text] [Related]
15. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
Moniri MR; Sun XY; Rayat J; Dai D; Ao Z; He Z; Verchere CB; Dai LJ; Warnock GL
Cancer Gene Ther; 2012 Sep; 19(9):652-8. PubMed ID: 22767216
[TBL] [Abstract][Full Text] [Related]
16. IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells.
Tecchio C; Huber V; Scapini P; Calzetti F; Margotto D; Todeschini G; Pilla L; Martinelli G; Pizzolo G; Rivoltini L; Cassatella MA
Blood; 2004 May; 103(10):3837-44. PubMed ID: 14726404
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
Ibrahim SM; Ringel J; Schmidt C; Ringel B; Müller P; Koczan D; Thiesen HJ; Löhr M
Pancreas; 2001 Jul; 23(1):72-9. PubMed ID: 11451151
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
19. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.
Grisendi G; Bussolari R; Cafarelli L; Petak I; Rasini V; Veronesi E; De Santis G; Spano C; Tagliazzucchi M; Barti-Juhasz H; Scarabelli L; Bambi F; Frassoldati A; Rossi G; Casali C; Morandi U; Horwitz EM; Paolucci P; Conte P; Dominici M
Cancer Res; 2010 May; 70(9):3718-29. PubMed ID: 20388793
[TBL] [Abstract][Full Text] [Related]
20. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.
Tur V; van der Sloot AM; Reis CR; Szegezdi E; Cool RH; Samali A; Serrano L; Quax WJ
J Biol Chem; 2008 Jul; 283(29):20560-8. PubMed ID: 18474604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
